From Nuclear Winter to Renewal: Biotech Investing for 2026

January 8, 2026 |

1 min read |

Jennifer Smith-Parker, BioSpace Insights

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing director, head of Biotech Private Equity at Ally Bridge Group, about how M &A dynamics, dealmaking and global partnerships are reshaping portfolio valuations and paths to growth in 2026.

> Listen on Spotify
> Listen on Apple Podcasts
> Listen on Amazon Music
> Listen on iHeart

After a prolonged funding chill, investors say 2026 is shaping up for continued M&A and dealmaking, and diversified bets beyond oncology and immunology.

Host

⁠Jennifer Smith-Parker⁠, Director of Insights, BioSpace

Guests

⁠Maha Katabi⁠, General Partner, Sofinnova Investments

⁠Andrew Lam⁠, Managing Director, Head of Biotech Private Equity, Ally Bridge Group (ABG)

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Jennifer Smith-Parker

Jennifer C. Smith-Parker is Director of Insights at BioSpace. She has been been immersed for 20 years in healthcare, first as a journalist and editor before pivoting to corporate, brand, and product communications. A skilled storyteller, she is adept at creating diverse content across platforms and crafting narratives that drive engagement, strengthen reputation, and deliver measurable growth. You can reach her at Jennifer.Smith-Parker@BioSpace.com.

BioSpace Insights

The BioSpace Insights teams performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.